ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Genesys Capital appoints Dr. Maxime Ranger as Venture Partner

January 13, 2022 GMT
Dr. Maxime Ranger (Photo: Lisa Logan Photography)
Dr. Maxime Ranger (Photo: Lisa Logan Photography)
Dr. Maxime Ranger (Photo: Lisa Logan Photography)

TORONTO & MONTREAL--(BUSINESS WIRE)--Jan 13, 2022--

Genesys Capital is pleased to announce the appointment of Dr. Maxime Ranger as a Venture Partner. Later this year, Dr. Ranger will transition from this role into the role of General Partner of Genesys Ventures IV LP. Genesys has enjoyed a long-standing relationship with Dr. Ranger as he has co-created and provided leadership to three biopharma companies alongside Genesys over the past 15 years, including most recently having co-founded and currently serving as CEO of Genesys portfolio company, Giiant Pharma.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005622/en/

Dr. Maxime Ranger (Photo: Lisa Logan Photography)

Dr. Ranger is a valuable addition to the senior investment team and will complement Genesys’ company building expertise with his extensive operating experience and immersion in the Quebec life science ecosystem. As part of the senior investment team, he will anchor Genesys co-creation and start-up activity in Montreal as the firm optimizes its ability to execute its unique company co-creation model in Quebec, one of North America’s leading innovation ecosystems.

ADVERTISEMENT

The firm first expanded its investment activity into the Quebec market in 2008. As Genesys has continued to execute on its local, co-creation investment strategy it has become increasingly important to maximize its reach beyond its current offices in Toronto and include a local footprint in Quebec. With up to 40% of the firm’s deal flow originating in Quebec, this team and footprint expansion represent a natural step in its evolution.

“Over the course of the last 15 years we have had the pleasure of working with Max across a number of projects, he is without a doubt a natural fit as a General Partner at Genesys”, said Jamie Stiff, Managing Director, Genesys Capital.

“As an entrepreneur, it has been a real privilege working with Genesys over the last 15 years. Sharing the same investment vision, it became logical for me to join the team and contribute to building start-up companies around disruptive technologies, in addition to shaping the Quebec life science ecosystem”, added Dr. Maxime Ranger.

Genesys expects to be making its first investments out of Genesys Ventures IV later this year.

About Genesys Capital

ADVERTISEMENT

Genesys Capital ( www.genesyscapital.com ) is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. Genesys is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys Capital accelerates the development of commercially viable emerging companies that represent disruptive life sciences investment opportunities. Portfolio companies include Affinium Pharmaceuticals (acquired by Debiopharm), Aptinyx (NASDAQ: APTX), Epocal (acquired by Alere, now Abbott Labs). Fusion Pharmaceuticals (NASDAQ: FUSN), Giiant Pharma (private), Inversago Pharma (private), Invitae (NYSE: NVTA), Ionalytics (acquired by Thermo Electron, now Thermo Fisher Scientific), Naurex (acquired by Allergan) and Profound Medical (NASDAQ: PROF).

View source version on businesswire.com:https://www.businesswire.com/news/home/20220113005622/en/

CONTACT: Media

Mariya Valerova

(416) 598-4900 x221

mariya@genesyscapital.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES FINANCE

SOURCE: Genesys Capital

Copyright Business Wire 2022.

PUB: 01/13/2022 11:45 AM/DISC: 01/13/2022 11:47 AM

http://www.businesswire.com/news/home/20220113005622/en